Intestinal tumors in neurofibromatosis 1 with special reference to fatal gastrointestinal stromal tumors (GIST)

Type 1 neurofibromatosis (NF1) is a genetic tumor predisposing Rasopathy. NF1 patients have an increased risk for developing benign and malignant tumors, but the occurrence of intestinal tumors has not been investigated at the population level.

[1]  S. Sleijfer,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  N. Arifa,et al.  Spectrum of gastrointestinal lesions of neurofibromatosis type 1: a pictorial review , 2018, Insights into Imaging.

[3]  Gang Ren,et al.  A correlation research of Ki67 index, CT features, and risk stratification in gastrointestinal stromal tumor , 2018, Cancer medicine.

[4]  L. Lino-Silva,et al.  Association of ki67 Index with Recurrence in Gastrointestinal Stromal Tumors , 2018, Journal of Gastrointestinal Cancer.

[5]  M. von Mehren,et al.  Advances and Challenges on Management of Gastrointestinal Stromal Tumors , 2018, Front. Oncol..

[6]  J. Zhong,et al.  Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors , 2018, Gastroenterology research and practice.

[7]  S. Grossman,et al.  Classification of gastrointestinal stromal tumor syndromes. , 2018, Endocrine-related cancer.

[8]  James S. Lawson,et al.  Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein–Barr Virus (EBV) , 2018, Front. Oncol..

[9]  H. Joensuu,et al.  Gastrointestinal Stromal Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Yu Zhou,et al.  Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors , 2017, Medicine.

[11]  J. Martín-Broto,et al.  GEIS guidelines for gastrointestinal sarcomas (GIST). , 2017, Cancer treatment reviews.

[12]  Kimberly J. Johnson,et al.  Neurofibromatosis type 1 , 2017, Nature Reviews Disease Primers.

[13]  S. Peltonen,et al.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Wada,et al.  “Wild type” GIST: Clinicopathological features and clinical practice , 2016, Pathology international.

[15]  K. Søreide,et al.  Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.

[16]  S. Hirota,et al.  Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I , 2015, Journal of Gastroenterology.

[17]  T. Vahlberg,et al.  Incidence and mortality of neurofibromatosis: a total population study in Finland. , 2015, The Journal of investigative dermatology.

[18]  T. Nishida,et al.  Submucosal tumors: Comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors , 2013, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[19]  J. Lasota,et al.  Gastrointestinal stromal tumors. , 2013, Gastroenterology clinics of North America.

[20]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[21]  O. Al-Shboul.  The Importance of Interstitial Cells of Cajal in the Gastrointestinal Tract , 2013, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[22]  A. Agaimy,et al.  Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. , 2012, International journal of clinical and experimental pathology.

[23]  S. Peltonen,et al.  The pathoetiology of neurofibromatosis 1. , 2011, The American journal of pathology.

[24]  M. Scarpa,et al.  A systematic review on the clinical diagnosis of gastrointestinal stromal tumors , 2008, Journal of surgical oncology.

[25]  C. Mussi,et al.  Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 , 2008, Clinical Cancer Research.

[26]  F. Speleman,et al.  Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. , 2006, Human molecular genetics.

[27]  H. Joensuu,et al.  NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics , 2005, The American journal of surgical pathology.

[28]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[29]  B. Korf.  Malignancy in neurofibromatosis type 1. , 2000, The oncologist.

[30]  A. Odén,et al.  Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population , 1997, Cancer.

[31]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.